Robust Q1; well-poised for further acceleration
03/05/21 -"Astra kicked-off 2021 on a promising note, from both a sales and profitability perspective. Besides a healthy (though somewhat slower) performance for the lynchpin oncology portfolio, the strong ..."
Pages
63
Language
English
Published on
03/05/21
You may also be interested by these reports :
13/11/25
The Q3 results exceeded the street’s expectations, driven by healthy top-line growth across all segments and a profitability beat (also aided by a ...
12/11/25
The Q3 profitability beat was driven by Crop Science, though Pharmaceuticals witnessed lower operating profits. Also, the management maintained its ...
10/11/25
The US government has agreed with Novo and Lilly to lower their weight-loss drugs’ prices, mainly in return for a three-year tariff exemption and ...
07/11/25
Genmab’s Q3 results surpassed the street’s expectations, driven by robust performance across most offerings, resulting in solid profitability ...